Geode Capital Management
LAB icon

Geode Capital Management’s Standard BioTools LAB Stock Holding History

Geode Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Sell
3,896,574
-3,392,762
-47% -$3.21M ﹤0.01% 3083
2026
Q1 		$6.7M Sell
7,289,336
-131,360
-2% -$159K ﹤0.01% 2596
2025
Q4 		$9.5M Sell
7,420,696
-48,221
-0.6% -$64.8K ﹤0.01% 2437
2025
Q3 		$9.71M Buy
7,468,917
+27,783
+0.4% +$36.4K ﹤0.01% 2432
2025
Q2 		$8.93M Buy
7,441,134
+235,677
+3% +$261K ﹤0.01% 2436
2025
Q1 		$7.78M Buy
7,205,457
+230,236
+3% +$323K ﹤0.01% 2438
2024
Q4 		$12.2M Buy
6,975,221
+25,504
+0.4% +$47.5K ﹤0.01% 2241
2024
Q3 		$13.4M Buy
6,949,717
+154,848
+2% +$303K ﹤0.01% 2201
2024
Q2 		$12M Buy
6,794,869
+4,087,943
+151% +$9.99M ﹤0.01% 2213
2024
Q1 		$7.34M Buy
2,706,926
+1,900,884
+236% +$4.59M ﹤0.01% 2505
2023
Q4 		$1.78M Buy
806,042
+48,228
+6% +$103K ﹤0.01% 3147
2023
Q3 		$2.2M Buy
757,814
+69,868
+10% +$183K ﹤0.01% 3049
2023
Q2 		$1.33M Sell
687,946
-26,101
-4% -$51.5K ﹤0.01% 3245
2023
Q1 		$1.39M Buy
714,047
+2,653
+0.4% +$5.24K ﹤0.01% 3197
2022
Q4 		$832K Buy
711,394
+3,591
+0.5% +$4.42K ﹤0.01% 3437
2022
Q3 		$778K Buy
707,803
+1,237
+0.2% +$1.87K ﹤0.01% 3522
2022
Q2 		$1.13M Sell
706,566
-632,190
-47% -$1.56M ﹤0.01% 3371
2022
Q1 		$4.81M Sell
1,338,756
-37,006
-3% -$128K ﹤0.01% 2818
2021
Q4 		$5.39M Buy
1,375,762
+26,003
+2% +$122K ﹤0.01% 2857
2021
Q3 		$8.89M Buy
1,349,759
+37,887
+3% +$249K ﹤0.01% 2536
2021
Q2 		$8.08M Buy
1,311,872
+42,952
+3% +$230K ﹤0.01% 2614
2021
Q1 		$5.74M Buy
1,268,920
+129,448
+11% +$711K ﹤0.01% 2722
2020
Q4 		$6.84M Buy
1,139,472
+48,574
+4% +$319K ﹤0.01% 2409
2020
Q3 		$8.11M Buy
1,090,898
+11,980
+1% +$82.7K ﹤0.01% 2086
2020
Q2 		$4.33M Buy
1,078,918
+43,792
+4% +$153K ﹤0.01% 2422
2020
Q1 		$2.63M Buy
1,035,126
+68,459
+7% +$225K ﹤0.01% 2524
2019
Q4 		$3.36M Sell
966,667
-40,667
-4% -$143K ﹤0.01% 2692
2019
Q3 		$4.66M Buy
1,007,334
+199,541
+25% +$1.57M ﹤0.01% 2423
2019
Q2 		$9.95M Buy
807,793
+168,692
+26% +$2.15M ﹤0.01% 1959
2019
Q1 		$8.49M Buy
639,101
+187,044
+41% +$1.97M ﹤0.01% 2007
2018
Q4 		$3.9M Buy
452,057
+132,549
+41% +$1.03M ﹤0.01% 2374
2018
Q3 		$2.39M Buy
319,508
+51,366
+19% +$365K ﹤0.01% 2788
2018
Q2 		$1.6M Buy
268,142
+11,457
+4% +$65.3K ﹤0.01% 2985
2018
Q1 		$1.5M Buy
256,685
+4,406
+2% +$28.9K ﹤0.01% 2924
2017
Q4 		$1.49M Buy
252,279
+21,429
+9% +$117K ﹤0.01% 2922
2017
Q3 		$1.16M Sell
230,850
-12,028
-5% -$50.6K ﹤0.01% 3056
2017
Q2 		$980K Buy
242,878
+24,557
+11% +$116K ﹤0.01% 3113
2017
Q1 		$1.24M Buy
218,321
+3,311
+2% +$21K ﹤0.01% 2916
2016
Q4 		$1.56M Buy
215,010
+8,897
+4% +$55.9K ﹤0.01% 2769
2016
Q3 		$1.65M Buy
206,113
+2,973
+1% +$27.3K ﹤0.01% 2674
2016
Q2 		$1.83M Buy
203,140
+2,570
+1% +$24.2K ﹤0.01% 2538
2016
Q1 		$1.62K Buy
200,570
+16,415
+9% +$118K ﹤0.01% 2598
2015
Q4 		$1.99M Sell
184,155
-2,266
-1% -$22.3K ﹤0.01% 2494
2015
Q3 		$1.51M Buy
186,421
+8,809
+5% +$139K ﹤0.01% 2623
2015
Q2 		$4.3M Buy
177,612
+763
+0.4% +$24.1K ﹤0.01% 1990
2015
Q1 		$7.45M Buy
176,849
+21,480
+14% +$849K ﹤0.01% 1599
2014
Q4 		$5.24M Buy
155,369
+917
+0.6% +$26K ﹤0.01% 1783
2014
Q3 		$3.78M Buy
154,452
+2,119
+1% +$59.6K ﹤0.01% 1936
2014
Q2 		$4.48M Sell
152,333
-286
-0.2% -$9.16K ﹤0.01% 1858
2014
Q1 		$6.72M Buy
152,619
+24,374
+19% +$1.07M ﹤0.01% 1543
2013
Q4 		$4.91M Buy
128,245
+23,857
+23% +$703K ﹤0.01% 1722
2013
Q3 		$2.29M Buy
104,388
+12,151
+13% +$239K ﹤0.01% 2090
2013
Q2 		$1.61M Buy
+92,237
New +$1.62M ﹤0.01% 2169

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Geode Capital Management's LAB Position: Q2 2026 in Review

Geode Capital Management reduced its Standard BioTools (LAB) stake by 47% in Q2 2026, selling an estimated $3.21M and leaving 3,896,574 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

Geode Capital Management first reported a position in LAB in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.4M in Q3 2024. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Geode Capital Management held 3,896,574 shares of Standard BioTools worth $3.21M as of Q2 2026.
  • Geode Capital Management sold 3,392,762 Standard BioTools shares in Q2 2026, an estimated $3.21M.
  • Standard BioTools made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3083 holding.
  • Geode Capital Management first reported a position in Standard BioTools in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Standard BioTools position peaked at $13.4M in Q3 2024.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.